PL2413902T3 - Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne - Google Patents

Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne

Info

Publication number
PL2413902T3
PL2413902T3 PL10754091T PL10754091T PL2413902T3 PL 2413902 T3 PL2413902 T3 PL 2413902T3 PL 10754091 T PL10754091 T PL 10754091T PL 10754091 T PL10754091 T PL 10754091T PL 2413902 T3 PL2413902 T3 PL 2413902T3
Authority
PL
Poland
Prior art keywords
aerosols
kits
methods
unit doses
pulmonary administration
Prior art date
Application number
PL10754091T
Other languages
English (en)
Polish (pl)
Inventor
Carlos A. Schuler
Rangachari Narasimhan
Original Assignee
Incarda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incarda Therapeutics, Inc. filed Critical Incarda Therapeutics, Inc.
Publication of PL2413902T3 publication Critical patent/PL2413902T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10754091T 2009-03-18 2010-03-18 Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne PL2413902T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
PCT/US2010/027740 WO2010107964A1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP10754091.6A EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (1)

Publication Number Publication Date
PL2413902T3 true PL2413902T3 (pl) 2020-01-31

Family

ID=42739985

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10754091T PL2413902T3 (pl) 2009-03-18 2010-03-18 Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne

Country Status (9)

Country Link
US (5) US8974828B2 (enExample)
EP (3) EP2413902B1 (enExample)
JP (5) JP2012520890A (enExample)
AU (1) AU2010226613B2 (enExample)
CA (2) CA2835771C (enExample)
DK (1) DK2413902T3 (enExample)
ES (3) ES3036464T3 (enExample)
PL (1) PL2413902T3 (enExample)
WO (1) WO2010107964A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA3114582A1 (en) 2010-12-22 2012-06-28 Syqe Medical Ltd. Method and system for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
TWI590837B (zh) * 2014-03-25 2017-07-11 林信湧 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
PL3160565T3 (pl) * 2014-06-30 2022-01-10 Syqe Medical Ltd. Urządzenia i systemy do dopłucnego dostarczania środków aktywnych
CN106604755B (zh) 2014-06-30 2020-08-11 Syqe医药有限公司 流量调节的吸入器装置
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
ES2778673T3 (es) * 2015-04-14 2020-08-11 Milestone Pharmaceuticals Inc Sales altamente solubles de un inhibidor de los canales de calcio de fenilalquilamina de corta acción y usos de las mismas
ES2874087T3 (es) 2016-01-06 2021-11-04 Syqe Medical Ltd Tratamiento terapéutico con dosis bajas
SG11201805788WA (en) 2016-02-01 2018-08-30 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019183470A2 (en) * 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
CN112533664A (zh) * 2018-06-05 2021-03-19 英凯达治疗公司 使用气雾剂诊断Brugada综合征的方法
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) * 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
CN114144177A (zh) * 2019-08-01 2022-03-04 英凯达治疗公司 抗心律失常制剂
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
AU2021400335A1 (en) 2020-12-17 2023-06-22 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
JP3202705B2 (ja) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
CN100358494C (zh) 1998-11-12 2008-01-02 弗兰克G·皮尔基威克兹 一种吸入给药系统
ATE331544T1 (de) 1999-05-28 2006-07-15 Nektar Therapeutics Gerät und verfahren zur aerosolisierung einer pharmazeutischen pulverzusammensetzung
ATE364381T1 (de) * 2000-04-17 2007-07-15 Vectura Ltd Formulierungen zur verwendung in inhalationsvorrichtungen
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
WO2002054868A2 (en) 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US20040197271A1 (en) 2001-03-20 2004-10-07 Kunka Robert Leonard Inhalation drug combinations
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
EP1450885B1 (en) * 2001-09-28 2015-04-22 Kurve Technology, Inc. Nasal nebulizer
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7334580B2 (en) 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
WO2004071368A2 (en) 2002-05-07 2004-08-26 The State University Of New York At Stony Brook Methods, devices and formulations for targeted endobronchial therapy
MXPA05007158A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceutica con un agente activo insoluble.
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
JP4931930B2 (ja) 2005-10-21 2012-05-16 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2668970B1 (en) 2006-10-25 2016-07-06 Novartis AG Powder dispersion apparatus
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
TW200840578A (en) * 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
EP2323648A4 (en) * 2008-08-14 2012-10-03 Uab Research Foundation AGAINST ARTHHYTHMIA, METHOD OF USE, IDENTIFICATION METHOD AND KITS THEREFOR
US8501727B2 (en) * 2008-08-22 2013-08-06 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
KR20160083953A (ko) * 2008-09-23 2016-07-12 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
WO2010107964A1 (en) 2010-09-23
EP2413902A4 (en) 2014-02-19
EP3552603B1 (en) 2024-11-06
EP2413902B1 (en) 2019-07-17
US20150313842A1 (en) 2015-11-05
CA2835771A1 (en) 2010-09-23
JP7071949B2 (ja) 2022-05-19
ES3036464T3 (en) 2025-09-19
US8974828B2 (en) 2015-03-10
EP3552602B1 (en) 2025-03-05
EP3552603A1 (en) 2019-10-16
ES2750359T3 (es) 2020-03-25
EP3552602C0 (en) 2025-03-05
JP2017160268A (ja) 2017-09-14
CA2755809C (en) 2014-02-18
EP3552603C0 (en) 2024-11-06
ES3003038T3 (en) 2025-03-10
JP2019019139A (ja) 2019-02-07
US20120003318A1 (en) 2012-01-05
AU2010226613A1 (en) 2011-09-29
JP6715305B2 (ja) 2020-07-01
EP2413902A1 (en) 2012-02-08
AU2010226613B2 (en) 2013-07-25
JP2012520890A (ja) 2012-09-10
US10045939B2 (en) 2018-08-14
DK2413902T3 (da) 2019-10-07
JP2015193657A (ja) 2015-11-05
CA2835771C (en) 2017-01-24
US20190060230A1 (en) 2019-02-28
US20180296480A1 (en) 2018-10-18
JP2019203032A (ja) 2019-11-28
US20180318213A1 (en) 2018-11-08
CA2755809A1 (en) 2010-09-23
EP3552602A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
PL2413902T3 (pl) Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
EP2753236A4 (en) METHOD FOR DETECTING R-WAVES
PL2678035T3 (pl) Pochodne fenalen-1-onu, sposób ich wytwarzania i zastosowanie
IL224375B (en) A method for measuring heart rate variability
EP2739974A4 (en) METHOD AND COMPOSITIONS FOR HEART ERROR MONITORING
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
IL232906A0 (en) Pyrazolopyridine derivatives, a process for their preparation and their medical use
GB201305198D0 (en) Kits, components and methods for tissue reconstruction
ZA201309662B (en) System,method ,apparatus and user interfaces for gaming and warering
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
EP2763998A4 (en) TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF
ZA201400766B (en) Belt-conveying installatio, method for operating the same, and use thereof
ZA201404074B (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
SI2320878T1 (sl) Monoterpeni za zdravljenje bolezni dihalnih poti, še zlasti bronhopulmonalnih bolezni
IL227544B (en) (r)- Leoplomide, a method for its preparation and its medical uses
IL248698B (en) History of 1-h-pyrrolidine-4,2-dione and processes for their preparation
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
ZA201105513B (en) 5-ht4 inhibitors for treating airway diseases,in particular asthma
IL228581A0 (en) Compounds and methods for treatment, diagnosis and detection of disease
PL392283A1 (pl) Nowe pochodne aldehydu lub kwasu 4-cykloheksylo-5-nitro-2-oksopentanowego, sposób ich wytwarzania oraz ich zastosowanie
IL222623A0 (en) Methods, compositions and kits for providing a therapeutic treatment
PL395184A1 (pl) Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu